Contineum Therapeutics (NASDAQ:CTNM) Given “Overweight” Rating at Morgan Stanley
Morgan Stanley reaffirmed their overweight rating on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research report released on Friday morning,Benzinga reports. The firm currently has a $25.00 price objective on the stock. A number of other analysts have also recently commented on CTNM. Royal Bank of Canada reissued an “outperform” rating and […]
Morgan Stanley reaffirmed their overweight rating on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research report released on Friday morning,Benzinga reports. The firm currently has a $25.00 price objective on the stock. A number of other analysts have also recently commented on CTNM. Royal Bank of Canada reissued an “outperform” rating and […]
